Taiwan
· Delayed Price · Currency is TWD Senhwa Biosciences Statistics
Total Valuation
Senhwa Biosciences has a market cap or net worth of TWD 4.18 billion. The enterprise value is 3.04 billion.
| Market Cap | 4.18B |
| Enterprise Value | 3.04B |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Senhwa Biosciences has 89.19 million shares outstanding.
| Shares Outstanding | 89.19M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 3.34% |
| Owned by Institutions (%) | 0.10% |
| Float | 67.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4,183.02 |
| PB Ratio | 3.52 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -10.41 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -10.76 |
Financial Position
The company has a current ratio of 48.44, with a Debt / Equity ratio of 1.65.
| Current Ratio | 48.44 |
| Quick Ratio | 48.13 |
| Debt / Equity | 1.65 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.07 |
| Interest Coverage | -531.65 |
Financial Efficiency
Return on equity (ROE) is -21.89% and return on invested capital (ROIC) is -14.16%.
| Return on Equity (ROE) | -21.89% |
| Return on Assets (ROA) | -14.03% |
| Return on Capital (ROIC) | -14.16% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.22% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +4.22% |
| 50-Day Moving Average | 50.53 |
| 200-Day Moving Average | 47.13 |
| Relative Strength Index (RSI) | 40.87 |
| Average Volume (20 Days) | 654,158 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Senhwa Biosciences had revenue of TWD 1.00 million and -291.54 million in losses. Loss per share was -3.27.
| Revenue | 1.00M |
| Gross Profit | 548,000 |
| Operating Income | -305.70M |
| Pretax Income | -290.28M |
| Net Income | -291.54M |
| EBITDA | -303.65M |
| EBIT | -305.70M |
| Loss Per Share | -3.27 |
Balance Sheet
The company has 1.17 billion in cash and 19.54 million in debt, giving a net cash position of 1.15 billion or 12.87 per share.
| Cash & Cash Equivalents | 1.17B |
| Total Debt | 19.54M |
| Net Cash | 1.15B |
| Net Cash Per Share | 12.87 |
| Equity (Book Value) | 1.19B |
| Book Value Per Share | 13.31 |
| Working Capital | 1.17B |
Cash Flow
In the last 12 months, operating cash flow was -280.10 million and capital expenditures -1.95 million, giving a free cash flow of -282.06 million.
| Operating Cash Flow | -280.10M |
| Capital Expenditures | -1.95M |
| Free Cash Flow | -282.06M |
| FCF Per Share | -3.16 |
Margins
| Gross Margin | 54.80% |
| Operating Margin | -30,570.10% |
| Pretax Margin | -29,027.70% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -28,205.70% |
Dividends & Yields
Senhwa Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -6.97% |
| FCF Yield | -6.74% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |